SPDR S&P Pharmaceuticals ETF (XPH)

NYSEARCA: XPH · Real-Time Price · USD
48.43
+0.09 (0.19%)
At close: Oct 8, 2025, 4:00 PM EDT
48.43
0.00 (0.00%)
After-hours: Oct 8, 2025, 6:30 PM EDT
0.19%
Assets$173.77M
Expense Ratio0.35%
PE Ratio13.85
Shares Out3.60M
Dividend (ttm)$0.51
Dividend Yield1.05%
Ex-Dividend DateSep 22, 2025
Payout FrequencyQuarterly
Payout Ratio14.49%
Volume33,750
Open48.52
Previous Close48.34
Day's Range48.08 - 48.66
52-Week Low35.22
52-Week High49.31
Beta0.60
Holdings52
Inception DateJun 19, 2006

About XPH

Fund Home Page

The SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol XPH
ETF Provider State Street
Index Tracked S&P Pharmaceuticals Select Industry

Top 10 Holdings

28.46% of assets
NameSymbolWeight
Corcept Therapeutics IncorporatedCORT3.10%
Tarsus Pharmaceuticals, Inc.TARS3.02%
Crinetics Pharmaceuticals, Inc.CRNX2.94%
Elanco Animal Health IncorporatedELAN2.84%
Pfizer Inc.PFE2.81%
Eli Lilly and CompanyLLY2.81%
Jazz Pharmaceuticals plcJAZZ2.77%
Ligand Pharmaceuticals IncorporatedLGND2.75%
Johnson & JohnsonJNJ2.71%
Organon & Co.OGN2.71%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 22, 2025$0.10263Sep 24, 2025
Jun 23, 2025$0.09587Jun 25, 2025
Mar 24, 2025$0.15332Mar 26, 2025
Dec 23, 2024$0.15484Dec 26, 2024
Sep 23, 2024$0.19471Sep 25, 2024
Jun 24, 2024$0.15573Jun 26, 2024
Full Dividend History

Performance

XPH had a total return of 11.91% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.84%.

News

Trump Trade War: New Tariffs on Drugs, Trucks, and Furniture Raise Inflation Risks

President Trump's new tariffs on drugs, trucks, and furniture reignite trade tensions, boosting U.S. manufacturers but raising global costs, pressuring exporters, and adding inflation risks.

9 days ago - FXEmpire

Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.

What unnerves investors is a lack of clarity on drug pricing.

Other symbols: PPH
11 days ago - WSJ

Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability

Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.

Other symbols: IHEPPHPJP
12 days ago - WSJ

Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1

President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...

Other symbols: FTXHIHEPPH
12 days ago - Fast Company

Pharma stocks gain, as Trump's tariff move actually could be a win for the sector

Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.

Other symbols: PJPPPHIHE
12 days ago - Market Watch

EU, Japan express confidence in capped US tariffs on drugs

The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals, which President Donald Trump said he would impose next week at a rate of 10...

Other symbols: EWJFLAXFLJP
12 days ago - Reuters

India's pharma stock crash after Trump's 100% tariff on branded drugs

India's pharmaceutical stocks were jolted on Friday, when President Donald Trump announced a 100% tariff on imported branded and patented drugs, effective October 1. The move sent shockwaves through g...

Other symbols: INDA
12 days ago - Invezz

Trump announces 100% tariffs on pharmaceuticals unless drug makers are building U.S. factories

President Donald Trump announced a raft of new tariffs late Thursday, including a 100% levy on imported pharmaceuticals unless their manufacturers are actively building factories in the U.S.

13 days ago - Market Watch

Trump announces 100% tariff on imports of branded or patented pharmaceuticals from October 1

The United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S., Pre...

13 days ago - Reuters

U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says

U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says

13 days ago - CNBC

Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.

Trump suggested steep chip-industry tariffs are coming, but there could be breaks for companies that invest in the U.S. Specifics are still sparse.

7 weeks ago - Market Watch

US FDA announces new program to boost domestic drug manufacturing

The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...

Other symbols: XLV
2 months ago - Reuters

Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.

The latest level of tariffs on the pharmaceutical industry is the highest yet from the president.

2 months ago - Market Watch

XPH: Healthcare Dashboard For July

This article provides a top-down view of the healthcare sector based on valuation and quality metrics. Healthcare providers are the most undervalued subsector, while pharma/biotech has the best qualit...

3 months ago - Seeking Alpha

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

4 months ago - Seeking Alpha

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...

Other symbols: IHEPPH
5 months ago - Benzinga

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

6 months ago - CNBC Television

Trump teases targeted tariffs on overseas drug manufacturers

With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...

Other symbols: AZNGSKIHENVSPJPSNY
6 months ago - Market Watch

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...

8 months ago - Seeking Alpha

XPH: A More Balanced Way To Get Exposure To Pharmaceuticals

The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceut...

1 year ago - Seeking Alpha

XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive

XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 20...

2 years ago - Seeking Alpha

XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals

XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.

2 years ago - Seeking Alpha

The Fall Of SVB: What It Means For Healthcare Startups

How SVB's collapse is impacting healthcare startups. Pfizer to buy Seagen for $43B.

Other symbols: BBCBBHFBTIBBIHEIHFIHI
2 years ago - Seeking Alpha

Will 2023 be the year that pharma M&A makes a comeback?

A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.

Other symbols: XBI
2 years ago - Market Watch

Can Health Care Stocks Outperform Again In 2023?

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

2 years ago - Seeking Alpha